Keynote Speakers
|
 |
|
G.Steven
Burrill |
Boris
Nikolic Senior Program Officer, Global Health Discovery Bill & Melinda Gates Foundation Download Presentation |
| Special Presentation | |
 |
|
|
Mary
Woolley |
|
|
Putting innovation to work - Where to, U.S.? |
|
|
In
the last few years, repeated calls have gone out for action on challenges
facing the life sciences in the U.S. Yet, little or no action has
been taken. The United States' ranking in technological readiness,
business sophistication, and market efficiency is slipping. Federal
agencies supporting the life sciences are not well coordinated.
Funding for the America COMPETES Act has stalled in Congress despite
bipartisan support and that of the President as well. What is wrong
with this picture? And what can the life sciences community do to
change or to influence it?
|
|
Panel Discussions
| Morning Panels | |
| 9:30 am - 10:10 am | |
|
Optimizing Partnerships and Strategic Alliances The impact of strategic alliances on shaping the pharmaceutical industry is unprecedented, and the trend is here to stay. How is large pharma going about identifying value in the startup arena, and what steps can early stage companies take to exploit large pharma’s quest for new technologies and products? This panel will include perspectives from large pharma partnering representatives who will highlight their unique approaches to strategic alliances and discuss case studies of deals involving small biotech and pharma. The panel will enable more informed decisions with respect to identifying synergies, approaching large pharma and structuring successful deals. Moderator:
|
Globality:
Beyond Globalization The increasing connectivity of the world ensures the ease of transmission of diseases (even exotic, hitherto-unknown ones) for one thing, posing new challenges to regions around the globe, and new opportunities for the study and mining of data from populations across the globe. Big pharma has been a global presence for over a century, with individual markets being served from a large R&D establishment dispersed in now-mature markets. But, the life sciences represent a great new frontier for new discoveries to become innovative products and services. It is also rapidly throwing up new business models and opportunities. "Globality" indicates disruption, by a range of players, from generics manufacturers (whose motivations and capabilities go beyond the expiration of patents) to niche-oriented innovators focused on hitherto-neglected diseases and conditions that have global relevance not easily exploited by the individual market-orientation of today's incumbents. This panel will discuss some of these trends and issues, and how they are being pursued in both emerging and mature markets. Moderator:
|
| Afternoon Panels | |
| 3:30 pm - 4:10 pm | |
|
Early Stage Investing: VC, Angel, Corporate and Alternative Sources of Funding The last year has been a challenging one for investors but there were many promising trends. VC-backed IPO's were up 33% while raising 60% more money than the previous year. VC and Angel funding was on the track to exceed 2006. M&A activity held its own. Funding continued shifting to later stage deals, however there is plenty of money for quality early stage companies. Also, Angel capital associations showed strong growth, individual Angels are returning to the fold, and VCs are making seed and early stage investments. There are more diverse sources of capital for seed and early stage companies. How to find them? How to best position to attract the right kind of capital? Moderator:
|
Life Sciences: The Good, The Bad
and The Ugly
In this session, our dynamic panelists will drill into the intersection of business, policy and society -- and ferret out what's good, bad, ugly and even downright frightening in life sciences today. From genetic privacy to patent issues, from stem cell policy to GMOS and personalized medicine, panelists will put the reality of life sciences under the bright light of a top-notch microscope, no-holds barred. Come prepared for some serious panel action -- leave with a lot of serious issues worth thinking about. Moderator:
|
